Jie Zhang

Jie Zhang

Auto-generated profile, based on publicly available information

Jie Zhang

Department of Endocrinology Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2024 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
WWWeihao Wang
Weihao Wang
JQJingtao Qiao
Jingtao Qiao
LZLina Zhang
Lina Zhang
JZJie Zhang
Jie Zhang
JLJingyi Luo
Jingyi Luo
LGLi xin Guo
Li xin Guo

26 August 2019 in Journal of International Medical Research
Verified
Journal Article
Open access
PDF file
JZJie Zhang
Jie Zhang
LTLin Tian
Lin Tian
LGLi xin Guo
Li xin Guo
Objective: Both obstructive sleep apnea–hypopnea syndrome (OSAHS) and type 2 diabetes mellitus (T2DM) are closely related to the renin-angiotensin-aldosterone system. We investigated whether hyperaldosteronemia is found in patients with OSAHS complicated by T2DM and whether continuous positive airway pressure (CPAP) treatment can significantly reduce the aldosterone level. Methods: Patients with T2DM were classified into an OSAHS group [apnea–hypopnea index (AHI) of ≥15] and a control group (without OSAHS; AHI of <5). The OSAHS group was exposed to CPAP for 7 days (7 h/day). Results: The plasma aldosterone, plasma renin, and urinary aldosterone levels were higher in the OSAHS than control group. The plasma aldosterone and renin levels were significantly lower after than before treatment in the OSAHS group, but they were still higher than the baseline levels in the control group. The post-treatment urinary aldosterone level was significantly higher in the OSAHS than control group. No correlation was found between the AHI and plasma renin, plasma aldosterone, and 24-hour urinary aldosterone levels. The blood glucose level in the OSAHS group did not significantly change after treatment. Conclusions: The plasma and urine aldosterone levels are increased in patients with concurrent T2DM and OSAHS and are significantly reduced by CPAP. Trial registration: ChiCTR-ION-16009837

1 October 2022 in Journal of Investigative Medicine
Verified
Journal Article
Closed access
PDF file
JZJie Zhang
Jie Zhang
TXTong-Zhang Xian
Tong-Zhang Xian
MWMing-Xiao Wu
Ming-Xiao Wu
CLChen Li
Chen Li
WWWeihao Wang
Weihao Wang
LGLi xin Guo
Li xin Guo
This is a secondary analysis of a randomized controlled trial (RCT) on the effects of the glucagon-like peptide-1 receptor agonists exenatide and insulin aspartate 30 injection on carotid intima-media thickness. Here, we report the renal outcomes of the intervention in patients with type 2 diabetes mellitus (T2DM). Data from the RCT study was used to evaluate the effect of exenatide or insulin given for 52 weeks on estimated glomerular filtration rate (eGFR) in patients with T2DM. The primary end point was the change in the eGFR from baseline between the exenatide and insulin groups in normal versus overweight patients and patients with obesity. The secondary end point was the correlation between change in eGFR and oxidative stress, glycemic control, and dyslipidemia. There was a significant difference in eGFR between the insulin and exenatide groups at 52 weeks (p=0.0135). Within the insulin group, the eGFR remained below baseline at 52 weeks in all patients, and there was an increase in body weight in the normal group compared with the overweight patients and patients with obesity. The opposite was observed in the exenatide group. A decrease in body weight was prominent in the exenatide group at 52 weeks (p<0.05), the eGFR was below baseline in overweight patients and patients with obesity and significantly above baseline in the normal group (p<0.05). The eGFR was positively correlated to 8-oxo-7,8-dihydroguanosine in the insulin group (p<0.05) but not the exenatide group. It can be concluded that compared with insulin, exenatide may improve renal function in overweight patients and patients with obesity more than in normal-weight patients with T2DM, but a further RCT is needed to confirm this effect.

1 January 2022 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
JZJie Zhang
Jie Zhang
TXTong-Zhang Xian
Tong-Zhang Xian
YTYu Teng
Yu Teng
XWXiuzhi Wang
Xiuzhi Wang
MWMing-Xiao Wu
Ming-Xiao Wu
LGLi xin Guo
Li xin Guo
Background. Exenatide is a glucagon‐like peptide‐1 receptor agonist that can reduce body weight. This study aimed to determine the efficacy of exenatide on body mass index (BMI) reduction in patients with type 2 diabetes mellitus (T2DM) with differing baseline body weight, blood glucose, and atherosclerotic status and to determine if there is a correlation between BMI reduction and cardiometabolic indices in these patients. Methods. This retrospective cohort study used data from our randomized controlled trial. A total of 27 T2DM patients treated with combination therapy of exenatide twice daily and metformin for 52 weeks were included. The primary endpoint was a change in the BMI from the baseline to week 52. The secondary endpoint was a correlation between BMI reduction and cardiometabolic indices. Findings. The BMIs of overweight and obesity patients and those with glycated hemoglobin (HbA1c) ≥ 9% significantly decreased −1.42 ± 1.48 kg/m2(P = 0.015) and −0.87 ± 0.93 kg/m2(P = 0.003), respectively, at the baseline after 52 weeks of treatment. There was no reduction in BMI in patients with normal weight, HbA1c <9%, the nonatherosclerosis group, and the atherosclerosis group. The decrease in BMI was positively correlated with changes in blood glucose, high‐sensitivity C‐reactive protein (hsCRP), and systolic blood pressure (SBP). Conclusion. BMI scores improved after exenatide treatment for 52 weeks in T2DM patients. Weight loss was affected by baseline body weight and blood glucose level. In addition, BMI reduction from the baseline to 52 weeks was positively correlated with baseline HbA1c, hsCRP, and SBP. Trial Registration. Chinese Clinical Trial Registry (ChiCTR-1800015658).

15 September 2026 in Metabolism Open
Verified
Journal Article
Open access
JZJie Zhang
Jie Zhang
WWWeihao Wang
Weihao Wang
FMFuli Man
Fuli Man
XWXiaoxia Wang
Xiaoxia Wang
QPQi Pan
Qi Pan
LGLi xin Guo
Li xin Guo

22 June 2023 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
HLHui Li
Hui Li
LZLina Zhang
Lina Zhang
XWXiaoxia Wang
Xiaoxia Wang
WWWeihao Wang
Weihao Wang
JZJie Zhang
Jie Zhang
LGLi xin Guo
Li xin Guo